liraglutide + naltrexone + bupropion + orlistat + phentermine + topiramate

This is a hypothetical combination drug consisting of six active pharmaceutical ingredients, each approved individually or in pairs for weight management and obesity. The components are: - **Liraglutide**: A glucagon-like peptide-1 (GLP-1) receptor agonist that suppresses appetite and slows gastric emptying, leading to reduced food intake. - **Naltrexone**: An opioid receptor antagonist that modulates the reward system involved in eating behavior. - **Bupropion**: A norepinephrine-dopamine reuptake inhibitor with antidepressant properties, also used for smoking cessation; it enhances satiety via central mechanisms. - **Orlistat**: An intestinal lipase inhibitor that reduces fat absorption from the gastrointestinal tract. - **Phentermine**: A sympathomimetic amine that acts as an appetite suppressant by increasing norepinephrine release in the hypothalamus. - **Topiramate**: An anticonvulsant with weight loss effects, thought to reduce appetite and increase satiety. Each of these drugs has been studied individually or as part of dual combinations (e.g., naltrexone-bupropion, phentermine-topiramate), but there is no evidence this specific six-drug combination exists as a marketed product. Such a combination would theoretically target multiple pathways involved in energy balance and appetite regulation[1][2][3][4][5].